ArticleThe Journal of allergy and clinical immunology2012
Cross-sector sponsorship of research in eosinophilic esophagitis: a collaborative model for rational drug development in rare diseases.
Article in The Journal of allergy and clinical immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Scientific journey to the first FDA-approved drug for eosinophilic esophagitis.The Journal of allergy and clinical immunology · 2022Article
- A Conceptual Approach to Understanding Treatment Response in Eosinophilic Esophagitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2019Review
- Strategies for eliciting and synthesizing evidence for guidelines in rare diseases.BMC medical research methodology · 2019Article
- Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study.The lancet. Gastroenterology & hepatology · 2018Observational
- Creating a multi-center rare disease consortium - the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).Translational science of rare diseases · 2017Article
- Sticky Steroids: In Search of an Approved Treatment for Eosinophilic Esophagitis.Journal of pediatric gastroenterology and nutrition · 2017Article
- Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis.Gastroenterology · 2016Observational
- Systematic review of outcome measures in pediatric eosinophilic esophagitis treatment trials.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2016Article
- Recognition and Assessment of Eosinophilic Esophagitis: The Development of New Clinical Outcome Metrics.Gastroenterology & hepatology · 2015Article
- Pediatric Eosinophilic Esophagitis Symptom Scores (PEESS v2.0) identify histologic and molecular correlates of the key clinical features of disease.The Journal of allergy and clinical immunology · 2015Article
- Development of drugs for celiac disease: review of endpoints for Phase 2 and 3 trials.Gastroenterology report · 2015Review
- How do gastroenterologists assess overall activity of eosinophilic esophagitis in adult patients?The American journal of gastroenterology · 2015Article
- Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis.Gastroenterology · 2014Observational
- Eosinophilic esophagitis: historical perspective on an evolving disease.Gastroenterology clinics of North America · 2014Article
- Unmet therapeutic needs in eosinophilic esophagitis.Digestive diseases (Basel, Switzerland) · 2014Review
- Non- and semi-invasive methods of monitoring eosinophilic esophagitis.Digestive diseases (Basel, Switzerland) · 2014Review
- Expanding research to provide an evidence base for nutritional interventions for the management of inborn errors of metabolism.Molecular genetics and metabolism · 2013Article
- Management of eosinophilic esophagitis from childhood to adulthood.Gastroenterology & hepatology · 2012Article
- Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis.The Journal of allergy and clinical immunology · 2012Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Like many rare diseases, eosinophilic esophagitis (EoE) is a poorly understood disorder, and assessment tools to accurately determine disease activity, remission, and natural history have long been inadequate. Clinical outcome end points able to assess the effectiveness of candidate therapeutic agents in clinical trials have been a particular deficiency and are urgently needed. With no approved therapy available to patients and with the prevalence of EoE on the increase, collaborative approaches to drug development are becoming ever more important. We describe a collaborative effort mobilized across institutions, including both the public and private sectors, that was initiated within the past 18 months expressly to address the need for further clinical research into the cause and treatment of EoE. Collaborators include the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition; the International Gastrointestinal Eosinophilic Researchers; and the US Food and Drug Administration. This effort has resulted in the elucidation of several parameters essential for effective EoE registration trials, including the need for clinically meaningful end points that measure changes in clinical symptoms in addition to the assessment of intraepithelial mucosal eosinophilia. The development and use of biomarkers, particularly in early-phase drug development, have become an important focus for investigations that might reduce clinical reliance on serial invasive monitoring. The concerted efforts described here to develop rational therapeutics and drug development paradigms in EoE also appear to provide a model for effective collaboration in the context of drug development for rare diseases and perhaps more generally for public health initiatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.